We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HPFS!! HIV, AIDS and Chronic Fatigue Immune Dysfunction
An SI Board Since February 1999
Posts SubjectMarks Bans
2 0 0
Emcee:  David Sirk Type:  Unmoderated
There has been some movement as of late with this stock. With the HUGE spread and the fact that the company was delisted I thought that this was just another Shell Scam. But after some exstensive D&D and a Few phone calls I have found out that even though it would seem that the Offices of HPFS have closed there doors and pulled the plug on the phone, THE Center for Special Immunology, Inc. {HPFS fully owns CSI}, is indeed a going concern there focus is.....

CFIDS is believed to result from a genetic failing occurring in the immune
response genes. This defect, when coupled with certain viral infections or other
activating factors, leads to a state of chronic immune activation, which causes
a variety of symptoms, including profound fatigue. CSI has developed treatment
protocols for chronic fatigue patients, the goal of which is to re-balance the
immune system or otherwise alleviate symptoms.

Through its efforts in research and practical
application, CSI has developed protocols for the treatment of HIV patients.
These protocols specify the treatments and therapies to be provided to HIV
patients, depending on the stage of the disease as determined by a
multi-parametric evaluation of clinical status, viral activity and immunologic
function. Treatment of HIV patients at CSI facilities by their affiliated
physicians is offered in accordance with these protocols. CSI has also developed
research protocols which govern the processes and record keeping practices to be
followed in specified studies performed by CSI. These studies may be undertaken
at CSI's initiative or in conjunction with a separate organization (e.g., a
pharmaceutical company), which would typically finance the study and pay certain
fees to CSI in return for conducting its portion of the clinical trial.

CFIDS is believed to result from a genetic failing occurring in the immune
In December, 1991, the Company acquired 100% of Center for Special
Immunology, Inc., a Delaware corporation ("CSI") and its subsidiaries which have
since become the only operating businesses of the Company. CSI owns and
operates an integrated health care delivery and clinical research system that
includes a multi-state network, operating in 9 states, of primary care and
clinical research facilities specializing in immune system disorders, consisting
primarily of HIV, AIDS and Chronic Fatigue Immune Dysfunction Syndrome (CFIDS).
The network also conducts multi-center trials in cooperation with biotechnology
and pharmaceutical companies. CSI was founded in 1986 by William M. Reiter,
M.D., FACP, and Paul J. Cimoch, M.D., FACP, who are both internationally
recognized research physicians. Dr. Reiter is currently Chairman of the Board
and Dr. Cimoch also currently serves on the Board.

Center for Special Immunology - Irvine, Irvine, CA (714) 753-0670 Cimoch
Center for Special Immunology - San Diego, San Diego, CA (619) 291-1122
Center Special Immunology - Chicago, , (312) 296-2400 Berger
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):